|
|
In
earlier trials, AIDSVAX™ vaccines
have reliably produced HIV antibody responses in trial
participants. These antibodies neutralize HIV virus in
test tubes. |
|
Objective
|
To
determine whether immunization with the AIDSVAX™
B/B vaccine protects volunteers at risk of becoming infected
with HIV-1. |
|
|
Volunteers
are inoculated with the vaccine or a placebo. The vaccine
is not made from live virus, and participants cannot
contract HIV or AIDS from the vaccine. The study is
ongoing for 3-4 years.
|
|
Inclusion
Criteria
|
- HIV-negative
male or female 18-60 y.o.
|
|
Status
__
|
Enrollment completed; study ongoing
--
|
|
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS Research Alliance
Institutional Review Board in January, 2001.
|
